MGC Pharmaceuticals: Completes Glioblastoma Study1

MGC Pharmaceuticals: Completes Glioblastoma Study1

MGC Pharmaceuticals Completes glioblastoma study

  • MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma
  • The Study was done between 2019-2022. The original formulation used THC. Later, it was replaced with cannabigerol.
  • Over18 patients were given 5800 cell test results to determine the best concentrations and ratios for cannabidiol and CBG.
  • TheResults showed that cannabinoids are effective in treating glioblastoma. The best CBD:CBG ratio was determined.
  • MGC Pharma The day ends with 35.3 Percent in the green and shares trading at 2.3%

Leave a Comment